GW cannabis-derived epilepsy drug gets positive FDA staff review

LONDON (Reuters) - GW Pharmaceuticals' cannabis-derived medicine for severe childhood epilepsy won a favorable review from U.S. Food and Drug Administration (FDA) staff on Tuesday, boosting hopes for its approval in the world's biggest drugs market.